Imidazopyridine compounds and uses thereof

A method for treating a disorder associated with P2X3 activity in an animal, wherein the disorder associated with P2X3 activity is selected from the group consisting of multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, endometriosis, depression, anxiety, a stress-related disorder, and drug addiction, and wherein the method comprises administering to the animal a therapeutically effective amount of a pharmaceutically active compound of Formula (I) or a salt thereof, wherein the compound of Formula (I) is:

• R1 is selected from the group consisting of cyano, halogen, methyl, and ethyl;
• R2 is selected from the group consisting of hydrogen, halogen, methyl, and ethyl;
• R3 is selected from the group consisting of halogen, methyl, and ethyl;
• R4 is selected from the group consisting of hydrogen, halogen, methyl, ethyl, and methoxy;
• as to R5 and R6;
• R5 and R6 are independently selected from the group consisting of hydrogen, C1-C6-alkyl, and hydroxy-C1-C6-alkyl;
• or
• R5 and R6, together with the nitrogen to which they are both attached, form a 5- or 6-member heterocycloalkyl, wherein:
• the heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, and C1-C4-alkyl;
• R7 and R8 are independently selected from the group consisting of hydrogen and C1-C4-alkyl;
• R9 is selected from the group consisting of C1-C6-alkyl, C3-C6-cycloalkyl, C1-C6-alkyl-C3-C6-cycloalkyl, halo-C1-C6-alkyl, C1-C6-alkoxy, halo-C1-C6-alkoxy, and C1-C6-alkoxy-C1-C6-alkyl;
• and
• X is selected from a bond, CH2, and O.